Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.

导出 LinkOut

翻译打印收藏纠错

第一作者： Eleonora,De Martin

第一单位： AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, INSERM Unit 1193, Univ Paris-Sud, Université Paris-Saclay, FHU Hépatinov, Villejuif, F-94800, France.

作者： Eleonora,De Martin ^[1] ; Jean-Marie,Michot ^[2] ; Olivier,Rosmorduc ^[3] ; Catherine,Guettier ^[4] ; Didier,Samuel ^[1]

作者单位： AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, INSERM Unit 1193, Univ Paris-Sud, Université Paris-Saclay, FHU Hépatinov, Villejuif, F-94800, France. ^[1] Département d'innovation thérapeutique et d'Essais Précoces (DITEP), Institut Gustave-Roussy, Université Paris Saclay, Villejuif, France. ^[2] AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, INSERM Unit 1193, Univ Paris-Sud, Université Paris-Saclay, FHU Hépatinov, Villejuif, F-94800, France.;Sorbonne-Université. ^[3] AP-HP Hôpital Bicêtre, Laboratoire Anatomie Pathologique, Le Kremlin-Bicêtre, France, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay, France. ^[4]

关键词 AIH, autoimmune hepatitis ALP, alkaline phosphatase ALT, alanine aminotransferase AMA, anti-mitochondrial antibodies ANA, anti-nuclear antibodies ASMA, anti-smooth muscles antibodies AST, aspartate aminotransferase CTLA-4, cytotoxic T lymphocyte-associated protein 4 Corticosteroid therapy DCR, disease control rate DILI, drug-induced liver injury GGT, gamma-glutamyltransferase HCC, hepatocellular carcinoma ICI, immune checkpoint inhibitor INR, international normalised ratio Immune-mediated hepatitis Immunotherapy Liver biopsy MMF, mycophenolate mofetil ORR, objective response rate OS, overall survival PD-1, programmed cell death 1 PD-L1-2, programmed cell death ligands 1-2 PFS, progression-free survival TKI, tyrosine kinase inhibitor UDCA, ursodeoxycholic acid ULN, upper limit of normal anti-LC1, anti-liver cytosol type-1 antibodies anti-LKM, anti-liver-kidney microsomal antibodies anti-SLA, anti-soluble liver antigen antibodies irAE, immune-related adverse event trAE, treatment-related adverse event

DOI 10.1016/j.jhepr.2020.100170

PMID 33205034

发布时间 2020-11-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

JHEP reports

2020年2卷6期

100170页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.

JHEP reports

相似文献

JHEP reports

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.

JHEP reports

相似文献

JHEP reports

相关期刊

检索历史清除